FibroBiologics, Inc. Common Stock Cash Flow Conversion Efficiency
FibroBiologics, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, FibroBiologics, Inc. Common Stock (FBLG) has a cash flow conversion efficiency ratio of -31.776x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.97 Million) by net assets ($125.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of FibroBiologics, Inc. Common Stock (2022–2025)
Cash flow conversion efficiency of FibroBiologics, Inc. Common Stock from 2022 to 2025. This chart illustrates how FibroBiologics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of FibroBiologics, Inc. Common Stock for real-time trading data and today's change.
FibroBiologics, Inc. Common Stock Cash Flow Conversion Ratio Explained
FibroBiologics, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
FibroBiologics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of FibroBiologics, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see market cap of FibroBiologics, Inc. Common Stock for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Planet Green Holdings Corp
NYSE MKT:PLAG
|
0.211x |
|
Sportshero Ltd
AU:SHO
|
-0.448x |
|
Orion Digital Corp.
NASDAQ:ORIO
|
0.041x |
|
Filter Vision Public Company Limited
BK:FVC
|
-0.091x |
|
iMBC Co.Ltd
KQ:052220
|
0.015x |
|
Renewables Infrastructure Grp
LSE:TRIG
|
0.022x |
|
Diversified Gateway Solutions Bhd
KLSE:0131
|
-0.015x |
|
Rifa Ind
KO:000760
|
0.011x |
Annual Cash Flow Conversion Efficiency for FibroBiologics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of FibroBiologics, Inc. Common Stock from 2022 to 2025. Review FibroBiologics, Inc. Common Stock free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $2.73 Million | $-11.90 Million | -4.351x | +14.82% |
| 2024-06-30 | $1.25 Million | $-6.40 Million | -5.109x | -602.06% |
| 2023-06-30 | $-4.00 Million | $-4.07 Million | 1.018x | -6.91% |
| 2022-06-30 | $-1.29 Million | $-1.41 Million | 1.093x | -- |
About FibroBiologics, Inc. Common Stock
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications. The company was founded in 2021 and is based in Houston, Texas.